Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Corboy

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Archives of Neurology|July 13, 2006
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expressionSean J Pittock, Brian G Weinshenker, Claudia F Lucchinetti, et al.
Neuro-Oncology|March 19, 2016
Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitationsJaishri O Blakeley, Stephen Joel Coons, John R Corboy, et al.
Multiple Sclerosis and Related Disorders|September 23, 2019
Rituximab-induced serum sickness in multiple sclerosis patientsAndrew B Wolf, Lana Zhovtis Ryerson, Krupa Pandey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2003
Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluidGregory P Owens, Alanna M Ritchie, Mark P Burgoon, et al.
Neurology|January 23, 2015
The effects of test-enhanced learning on long-term retention in AAN annual meeting coursesDouglas P Larsen, Andrew C Butler, Wint Y Aung, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2004
Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosisAlanna M Ritchie, Donald H Gilden, R Anthony Williamson, et al.
Neurology|January 13, 2019
Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosisJustin M Honce, Kavita V Nair, Stefan Sillau, et al.
The Lancet. Neurology|June 23, 2023
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trialJohn R Corboy, Robert J Fox, Ilya Kister, et al.
Frontiers in Physiology|November 3, 2018
Adjustments in Torque Steadiness During Fatiguing Contractions Are Inversely Correlated With IQ in Persons With Multiple SclerosisJeffrey R Gould, Andrew E Reineberg, Brice T Cleland, et al.
Frontiers in Neurology|October 19, 2020
Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer AcetateJustin M Honce, Kavita V Nair, Brian D Hoyt, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Archives of Neurology|July 13, 2006
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expressionSean J Pittock, Brian G Weinshenker, Claudia F Lucchinetti, et al.
Neuro-Oncology|March 19, 2016
Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitationsJaishri O Blakeley, Stephen Joel Coons, John R Corboy, et al.
Multiple Sclerosis and Related Disorders|September 23, 2019
Rituximab-induced serum sickness in multiple sclerosis patientsAndrew B Wolf, Lana Zhovtis Ryerson, Krupa Pandey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2003
Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluidGregory P Owens, Alanna M Ritchie, Mark P Burgoon, et al.
Neurology|January 23, 2015
The effects of test-enhanced learning on long-term retention in AAN annual meeting coursesDouglas P Larsen, Andrew C Butler, Wint Y Aung, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2004
Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosisAlanna M Ritchie, Donald H Gilden, R Anthony Williamson, et al.
Neurology|January 13, 2019
Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosisJustin M Honce, Kavita V Nair, Stefan Sillau, et al.
The Lancet. Neurology|June 23, 2023
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trialJohn R Corboy, Robert J Fox, Ilya Kister, et al.
Frontiers in Physiology|November 3, 2018
Adjustments in Torque Steadiness During Fatiguing Contractions Are Inversely Correlated With IQ in Persons With Multiple SclerosisJeffrey R Gould, Andrew E Reineberg, Brice T Cleland, et al.
Frontiers in Neurology|October 19, 2020
Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer AcetateJustin M Honce, Kavita V Nair, Brian D Hoyt, et al.
Pageof 9